难治性-话题@MedSci

#难治性#

683篇内容 | 2670人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1528802, encodeId=86731528802b0, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Haemat：瘤内注射TTI-621治疗复发性或难治性蕈样真菌病或Sézary综合征的安全性, objectType=article, longId=218260, objectId=769721826066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769721826066, replyNumber=0, likeNumber=64, createdTime=2021-10-10, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769721826066, moduleTitle=Lancet Haemat：瘤内注射TTI-621治疗复发性或难治性蕈样真菌病或Sézary综合征的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=769721826066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528801, encodeId=48ac15288017e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Oncol：卡瑞珠单抗联合阿帕替尼有望成为化疗难治性/复发性妊娠滋养细胞肿瘤的挽救治疗方案！, objectType=article, longId=218250, objectId=f5da2182509d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5da2182509d, replyNumber=0, likeNumber=86, createdTime=2021-10-10, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5da2182509d, moduleTitle=Lancet Oncol：卡瑞珠单抗联合阿帕替尼有望成为化疗难治性/复发性妊娠滋养细胞肿瘤的挽救治疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5da2182509d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528800, encodeId=9b8e1528800bd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效, objectType=article, longId=218182, objectId=cf9921818260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf9921818260, replyNumber=0, likeNumber=83, createdTime=2021-10-08, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf9921818260, moduleTitle=Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf9921818260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528799, encodeId=afaa1528e9972, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=JGH: 环孢素A与英夫利昔单抗治疗激素难治性急性重症溃疡性结肠炎疗效比较, objectType=article, longId=217290, objectId=167521e290ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=167521e290ee, replyNumber=0, likeNumber=74, createdTime=2021-09-20, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=167521e290ee, moduleTitle=JGH: 环孢素A与英夫利昔单抗治疗激素难治性急性重症溃疡性结肠炎疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=167521e290ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528798, encodeId=a9591528e9889, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：长春新碱-伊立替康方案加用替莫唑胺可改善复发/难治性横纹肌肉瘤患者的生存预后, objectType=article, longId=217221, objectId=d47b21e2212b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d47b21e2212b, replyNumber=0, likeNumber=93, createdTime=2021-09-18, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d47b21e2212b, moduleTitle=J Clin Oncol：长春新碱-伊立替康方案加用替莫唑胺可改善复发/难治性横纹肌肉瘤患者的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d47b21e2212b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528797, encodeId=836c1528e9778, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur J Cancer：原发难治性滤泡性淋巴瘤的不良预后和高组织转化率, objectType=article, longId=217117, objectId=ae8721e117eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae8721e117eb, replyNumber=0, likeNumber=105, createdTime=2021-09-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae8721e117eb, moduleTitle=Eur J Cancer：原发难治性滤泡性淋巴瘤的不良预后和高组织转化率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae8721e117eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528796, encodeId=e9491528e969e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！, objectType=article, longId=217100, objectId=dbfb21e1006b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbfb21e1006b, replyNumber=0, likeNumber=66, createdTime=2021-09-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbfb21e1006b, moduleTitle=Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbfb21e1006b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528795, encodeId=4d801528e9581, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=TAMO：阿帕替尼在难治性转移性胆道癌中的疗效和安全性, objectType=article, longId=217015, objectId=29e621e0156d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29e621e0156d, replyNumber=0, likeNumber=83, createdTime=2021-09-14, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29e621e0156d, moduleTitle=TAMO：阿帕替尼在难治性转移性胆道癌中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29e621e0156d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528794, encodeId=879f1528e94ef, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, objectType=article, longId=216944, objectId=046e21694492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046e21694492, replyNumber=0, likeNumber=71, createdTime=2021-09-12, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046e21694492, moduleTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046e21694492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528793, encodeId=bb931528e9392, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=216768, objectId=ddae216e6887, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddae216e6887, replyNumber=0, likeNumber=73, createdTime=2021-09-08, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddae216e6887, moduleTitle=Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddae216e6887)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528792, encodeId=ef4c1528e92d2, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：维奈托克单药治疗复发/难治性非霍奇金淋巴瘤的长期随访结果, objectType=article, longId=216691, objectId=f8e221669147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8e221669147, replyNumber=0, likeNumber=74, createdTime=2021-09-06, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e221669147, moduleTitle=Clin Cancer Res：维奈托克单药治疗复发/难治性非霍奇金淋巴瘤的长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8e221669147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528791, encodeId=04331528e9122, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur J Cancer：赛帕利单抗(GLS-010)治疗中国复发或难治性经典霍奇金淋巴瘤患者的疗效和安全性, objectType=article, longId=216599, objectId=109521659914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=109521659914, replyNumber=0, likeNumber=59, createdTime=2021-09-03, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=109521659914, moduleTitle=Eur J Cancer：赛帕利单抗(GLS-010)治疗中国复发或难治性经典霍奇金淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=109521659914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528790, encodeId=b71c1528e9086, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Dermatol Surg：皮秒亚历山大激光治疗亚洲人难治性黄褐斑的疗效, objectType=article, longId=216588, objectId=4406216588a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4406216588a7, replyNumber=0, likeNumber=67, createdTime=2021-09-03, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4406216588a7, moduleTitle=Dermatol Surg：皮秒亚历山大激光治疗亚洲人难治性黄褐斑的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4406216588a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528789, encodeId=72151528e892b, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性, objectType=article, longId=216567, objectId=da4821656e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da4821656e3b, replyNumber=0, likeNumber=67, createdTime=2021-09-03, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da4821656e3b, moduleTitle=J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da4821656e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528788, encodeId=1d9c1528e88dd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Blood Cancer J：奥比妥珠单抗+阿特珠单抗+来那度胺可有效治疗复发/难治性滤泡性淋巴瘤！, objectType=article, longId=216221, objectId=210121622181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210121622181, replyNumber=0, likeNumber=85, createdTime=2021-08-25, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210121622181, moduleTitle=Blood Cancer J：奥比妥珠单抗+阿特珠单抗+来那度胺可有效治疗复发/难治性滤泡性淋巴瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=210121622181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528787, encodeId=da9e1528e8753, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=EHJ：“宝藏药”沙库巴曲-缬沙坦作为治疗HFpEF合并难治性高血压患者的疗效, objectType=article, longId=216137, objectId=072321613e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=072321613e0b, replyNumber=0, likeNumber=75, createdTime=2021-08-23, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=072321613e0b, moduleTitle=EHJ：“宝藏药”沙库巴曲-缬沙坦作为治疗HFpEF合并难治性高血压患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=072321613e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528786, encodeId=8ff11528e8680, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Oncol：乐伐替尼+依托泊苷+异环磷酰胺，复发/难治性骨肉瘤的新联合治疗方案？, objectType=article, longId=215975, objectId=0cf32159e5f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cf32159e5f1, replyNumber=0, likeNumber=78, createdTime=2021-08-20, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cf32159e5f1, moduleTitle=Lancet Oncol：乐伐替尼+依托泊苷+异环磷酰胺，复发/难治性骨肉瘤的新联合治疗方案？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cf32159e5f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528785, encodeId=21191528e85e3, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clinical &Translational Gastroenterology: 肝性脑病史不是难治性腹水经颈静脉肝内门体分流术的禁忌症, objectType=article, longId=215815, objectId=9dc52158153c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dc52158153c, replyNumber=0, likeNumber=28, createdTime=2021-08-18, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dc52158153c, moduleTitle=Clinical &Translational Gastroenterology: 肝性脑病史不是难治性腹水经颈静脉肝内门体分流术的禁忌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dc52158153c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528784, encodeId=83931528e84d6, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Blood：本妥昔单抗联合纳武单抗挽救治疗复发/难治性霍奇金淋巴瘤的长期预后, objectType=article, longId=215771, objectId=a6f3215e7119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6f3215e7119, replyNumber=0, likeNumber=62, createdTime=2021-08-17, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6f3215e7119, moduleTitle=Blood：本妥昔单抗联合纳武单抗挽救治疗复发/难治性霍奇金淋巴瘤的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6f3215e7119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528783, encodeId=b1d11528e83cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！, objectType=article, longId=215765, objectId=00d1215e657e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00d1215e657e, replyNumber=0, likeNumber=78, createdTime=2021-08-17, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00d1215e657e, moduleTitle=J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00d1215e657e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

难治性

2020-05-29

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Haemat：瘤内注射TTI-621治疗复发性或难治性蕈样真菌病或Sézary综合征的安全性

2021-10-10

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Oncol：卡瑞珠单抗联合阿帕替尼有望成为化疗难治性/复发性妊娠滋养细胞肿瘤的挽救治疗方案！

2021-10-10

freve (审核中...)

前往app查看评论内容

#难治性#

Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效

2021-10-08

freve (审核中...)

前往app查看评论内容

#难治性#

JGH: 环孢素A与英夫利昔单抗治疗激素难治性急性重症溃疡性结肠炎疗效比较

2021-09-20

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：长春新碱-伊立替康方案加用替莫唑胺可改善复发/难治性横纹肌肉瘤患者的生存预后

2021-09-18

freve (审核中...)

前往app查看评论内容

#难治性#

Eur J Cancer：原发难治性滤泡性淋巴瘤的不良预后和高组织转化率

2021-09-16

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！

2021-09-16

freve (审核中...)

前往app查看评论内容

#难治性#

TAMO：阿帕替尼在难治性转移性胆道癌中的疗效和安全性

2021-09-14

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！

2021-09-12

freve (审核中...)

前往app查看评论内容

#难治性#

Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效

2021-09-08

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：维奈托克单药治疗复发/难治性非霍奇金淋巴瘤的长期随访结果

2021-09-06

freve (审核中...)

前往app查看评论内容

#难治性#

Eur J Cancer：赛帕利单抗(GLS-010)治疗中国复发或难治性经典霍奇金淋巴瘤患者的疗效和安全性

2021-09-03

freve (审核中...)

前往app查看评论内容

#难治性#

Dermatol Surg：皮秒亚历山大激光治疗亚洲人难治性黄褐斑的疗效

2021-09-03

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：新型二代CD19-CAR T细胞治疗复发/难治性B-ALL成人患者的效果和安全性

2021-09-03

freve (审核中...)

前往app查看评论内容

#难治性#

Blood Cancer J：奥比妥珠单抗+阿特珠单抗+来那度胺可有效治疗复发/难治性滤泡性淋巴瘤！

2021-08-25

freve (审核中...)

前往app查看评论内容

#难治性#

EHJ：“宝藏药”沙库巴曲-缬沙坦作为治疗HFpEF合并难治性高血压患者的疗效

2021-08-23

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Oncol：乐伐替尼+依托泊苷+异环磷酰胺，复发/难治性骨肉瘤的新联合治疗方案？

2021-08-20

freve (审核中...)

前往app查看评论内容

#难治性#

Clinical &Translational Gastroenterology: 肝性脑病史不是难治性腹水经颈静脉肝内门体分流术的禁忌症

2021-08-18

freve (审核中...)

前往app查看评论内容

#难治性#

Blood：本妥昔单抗联合纳武单抗挽救治疗复发/难治性霍奇金淋巴瘤的长期预后

2021-08-17

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！

2021-08-17

科室
- - 订阅+
  - 更多科室
工具
服务